null

Pembrolizumab Biosimilar (Anti-PD-1) Antibody (HDBS0006)

SKU:
HDBS0006
Antibody Type:
Biosimilar Reference Antibody
Modifications:
PE-Conjugated
Applications:
IHC
FC
Drug Development
Inflammatory Response Assays
Pharmacokinetics
Disease Area:
Cancer Immunotherapy
Disease Area:
Autoimmune Diseases
Protein:
PD-1
Reactivity:
Human
Host Species:
Chimeric Humanized
Isotype:
IgG4
  • Anti-PD-1 pembrolizumab biosimilar mAb HDBS0006
  • Anti-PD-1 pembrolizumab biosimilar mAb HDBS0006
  • Anti-PD-1 pembrolizumab biosimilar mAb HDBS0006
€399

Description

system_update_altDatasheet

Pembrolizumab (Anti-PD-1) Biosimilar Antibody (HDBS0006)

The Anti-PD-1 Pembrolizumab Biosimilar MAb (HDBS0006) is a monoclonal antibody designed for research involving PD-1, a cell surface receptor that plays a key role in regulating immune responses. The antibody is highly specific and reactive with human samples, making it ideal for use in various research applications including Western blotting and immunohistochemistry.PD-1, also known as programmed cell death protein 1, is an immune checkpoint protein that inhibits T cell activation and plays a critical role in maintaining immune tolerance.

Blockade of PD-1 has shown promise in the treatment of various cancers by restoring T cell function and activating anti-tumor immune responses. The Anti-PD-1 Pembrolizumab Biosimilar MAb (HDBS0006) is a valuable tool for studying the role of PD-1 in cancer immunotherapy and for developing novel therapies that target this immune checkpoint pathway. Its high specificity and sensitivity make it a reliable reagent for researchers working in the fields of immunology, oncology, and drug development.